Business Of Biotech BoB@JPM: Brian Hilberdink, Boehringer Ingelheim
4 snips
Feb 2, 2026 Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim and veteran commercial leader, discusses new opportunities in obesity and upcoming launch priorities. He explains how private ownership shapes long-term R&D, Boehringer's deal focus and adjacencies, and using AI to sharpen commercialization. He also covers market conditioning, CKD awareness, and regulators speeding HER2 NSCLC review.
AI Snips
Chapters
Transcript
Episode notes
Turning Leo Into A U.S. Growth Engine
- Brian described transforming Leo Pharma's U.S. business to be the primary growth driver ahead of an IPO.
- He cited adding novel dermatology treatments and expanding the portfolio as key achievements.
Private Ownership Enables Long‑Range R&D
- Private ownership lets Boehringer take a long-range view on R&D and market-building.
- Brian highlighted 27%+ R&D spend as a sustainable advantage for many shots on goal.
Use Market Conditioning To Increase Diagnosis
- Long-term private funding lets Boehringer invest in market conditioning like CKD screening campaigns.
- Brian described a Detect the SOS campaign to drive urine microalbumin testing and early intervention.